Sino-Singapore Jingwei, May 8th. A few days ago, Beijing Kexing Zhongwei Company, a subsidiary of Kexing, was accused of "maliciously detaining year-end awards and illegal layoffs."
According to the Beijing Public Legal Service website, some netizens left a message saying: He joined Beijing Kexing Zhongwei on February 1, 2021, and served as a lamp inspection post. In 2021, the company verbally promised to use 10% of the company's revenue for the year as a year-end bonus.
However, at the 2022 annual meeting, the company used the excuse that "Kexing is too limelight, so keep a low profile", and promised to "not issue year-end bonuses for now, and then issue them when the popularity drops."
However, the netizen said that on February 18, 2022, the personnel informed him for an interview and informed the company that layoffs were required. There were two options: 1. Resign yourself, and the company will pay N+1 compensation; 2. The company will take an indefinite holiday, and the salary will be based on Beijing. 80% of the city's minimum wage is paid, and part-time jobs are not allowed.
"When asked about the year-end bonus, HR said there was no year-end bonus, and was deceived by HR and induced to sign the termination of the labor contract."
The netizen also said that Beijing Kexing Zhongwei has successively laid off staff from February to April. After the last wave of layoffs on April 23, the 2021 year-end bonus will be issued to the remaining staff on April 25.
"In order to reduce the amount of compensation, Sinovac maliciously withheld the 2021 year-end bonus and maliciously reduced the compensation for dismissal. After negotiating with the company, the company gave an overlord clause, the base of the year-end bonus is half of the remaining employees, and it refused to compensate the compensation, with a tough attitude and bullying. ."
It is worth mentioning that there is also a post on Zhihu, "How to evaluate Kexing Zhongwei first layoffs in 2022, and then distributes 2021 year-end awards?" Many netizens said they had the same experience.
Some netizens said on April 26: I was on the night shift on the 21st, and I received a notice on the morning of the 22nd. HR forced me to sign.
Signed on the 22nd, and the year-end bonus was issued on the 25th.
The netizens who left a message on the Beijing Public Legal Service Website called "Beijing Kexing Zhongwei Biotechnology Co., Ltd.", and Sino-Singapore Jingwei only found "Beijing Kexing Zhongwei Biotechnology Co., Ltd." through the official website of Kexing.
Kexing's official website shows that Kexing Holding Biotechnology Co., Ltd. is a bio-high-tech enterprise headquartered in Beijing and is currently listed on NASDAQ.
The company owns Beijing Kexing Biological Products Co., Ltd., Kexing (Dalian) Vaccine Technology Co., Ltd., Beijing Kexing Zhongwei Biotechnology Co., Ltd., and Kexing Holdings (Singapore) Co., Ltd. through its wholly-owned subsidiary Kexing Holdings (Hong Kong) Co., Ltd. The company and Beijing Kexing Zhongyi Biopharmaceutical Co., Ltd. are five enterprises.
The netizen's revelations that "Kexing is too popular" is mainly because of the new coronavirus inactivated vaccine.
According to the official website, the new coronavirus inactivated vaccine (Kellife®) is one of Kexing's marketed products. It will be listed in China with conditions on February 5, 2021. It is included in the World Health Organization's emergency use list, and its annual production capacity exceeds 2 billion doses, approved for use in more than 50 countries/regions/institutions around the world.
As of November 2021, the cumulative global supply has exceeded 2.3 billion doses, and the cumulative vaccination has reached 1.9 billion doses.
And Kexing's new coronavirus inactivated vaccine is in charge of Beijing Kexing Zhongwei.
According to the Tianyancha APP, Beijing Kexing Zhongwei was established in May 2009 with a registered capital of US$40.5132 million, its legal representative is Yin Weidong, and its business status is in existence. Its registered address is located in Daxing Biomedical Industry Base, Zhongguancun Science and Technology Park, Daxing District, Beijing.
How much money will Beijing Kexing Zhongwei earn in 2021?
In the company's shareholder information, the sixth largest shareholder is Xie Qirun.
This person may be unfamiliar to everyone, but it is no stranger to mention Sino Bio, Xie Qirun is the chairman of Sino Biopharmaceutical Co., Ltd. (Hong Kong stock, 01177).
On March 31, Sino Biopharmaceuticals released its 2021 financial report in Hong Kong, showing that the annual operating income was 26.86 billion yuan, a year-on-year increase of 13.6%; the net profit attributable to the parent was 14.61 billion yuan, a year-on-year increase of 427.2%.
When talking about the investment in associates and joint ventures in the financial report, Sino Biopharma stated that Beijing Kexing Zhongwei performed particularly well during the year. In the company's financial statements, it was listed as an associate and accounted for using the equity method, bringing the company 136.31 per cent for the year. The profit contribution of 100 million yuan, after deducting relevant taxes, will bring the actual profit to 12.379 billion yuan.
Sino Biopharmaceutical holds a 15.03% stake in Beijing Kexing Zhongwei. Based on this calculation, Beijing Kexing Zhongwei's net profit after tax in 2021 is about 82.4 billion yuan.
(Sino-Singapore Jingwei APP)